Symbols

MRKR

Marker Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MRKR

Marker Therapeutics, Inc.

A clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for hematological malignancies and solid tumor indications

Industry

Biological Technology

Established Date

Listing Date

11/08/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.markertherapeutics.com

Security Type

Common stock

Office address

2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021

Business

Introduction

Marker Therapeutics, Inc., was originally incorporated under the laws of Nevada in 1991 and re-incorporated in Delaware in October 2018. The company is a clinical-stage immuno-oncology company developing novel T-cell immunotherapies using its multi-antigen recognition T-cell technology. Its method is designed to target a variety of tumor-associated antigens to treat hematological malignancies and solid tumors without the need for genetic modification.

Company Financials

EPS

MRKR has released its 2025 Q4 earnings. EPS was reported at -0.09, versus the expected -0.77, beating expectations. The chart below visualizes how MRKR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MRKR has released its 2025 Q4 earnings report, with revenue of 1.10M, reflecting a YoY change of -51.00%, and net profit of -1.70M, showing a YoY change of 55.62%. The Sankey diagram below clearly presents MRKR's revenue sources and cost distribution.